Clinical and Experimental Reproductive Medicine-CERM最新文献

{"title":"The value of endometrial scratch injury in infertile women trying to conceive through non-in vitro fertilization cycles: A systematic review and meta-analysis.","authors":"Nour A M El-Goly, Ahmed M Maged, Nehal Bassiouny, Safaa I Mahmoud, Amira Shoab","doi":"10.5653/cerm.2024.07612","DOIUrl":"10.5653/cerm.2024.07612","url":null,"abstract":"<p><p>To assess the effects of endometrial scratch injury (ESI) in infertile couples seeking fertility through non-in vitro fertilization (IVF) cycles. We conducted a comprehensive search of MEDLINE, EMBASE, Web of Science, Scopus, the Cochrane Library, and Google Scholar from their inception through August 2023. The search terms included 'endometrial scratch,' 'infertility,' 'implantation,' 'intrauterine insemination (IUI),' and their corresponding MeSH terms. We included all published and unpublished randomized controlled trials involving ESI in women undergoing either natural or IUI cycles. The ESIs varied in severity and were performed during either the follicular or luteal phase of the same or preceding cycle. Our review encompassed 32 studies, totaling 5,897 participants. Of these, seven studies with 1,094 participants assessed ESI in natural cycles, while 25 studies with 4,803 participants evaluated it in IUI cycles. The data extracted included trial location, number of participants, inclusion and exclusion criteria for participants, details of the ESI, and outcome parameters (trial registration: CRD42023434127). ESI significantly increased the clinical pregnancy rate (odds ratio [OR], 2.06; 95% confidence interval [CI], 1.72 to 2.47; p<0.001), ongoing pregnancy/live birth rate (OR, 1.68; 95% CI, 1.32 to 2.13; p<0.001), and chemical pregnancy rate (OR, 2.32; 95% CI, 1.79 to 3.00; p<0.001). However, it had no significant effect on the rates of multiple pregnancy, miscarriage, and ectopic pregnancy (p>0.05). ESI improved the clinical pregnancy rate, ongoing pregnancy/live birth rate, and chemical pregnancy rate in both natural and IUI cycles.</p>","PeriodicalId":46409,"journal":{"name":"Clinical and Experimental Reproductive Medicine-CERM","volume":"52 4","pages":"310-333"},"PeriodicalIF":1.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12682415/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145702316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assisted reproductive technology trends in Korea: Annual report for 2022.","authors":"Dayong Lee, Myeong Eun Seong, Hye Jin Chang, Young Sik Choi, Hee Jin Lim, Youngjun Choi, Kyungjoo Hwang, Jin Suk Jo, Jung Ryeol Lee","doi":"10.5653/cerm.2025.08872","DOIUrl":"10.5653/cerm.2025.08872","url":null,"abstract":"<p><strong>Objective: </strong>The Korean government implemented national insurance coverage for infertility treatment in 2017 and established a nationwide infertility treatment data collection system in 2018. This report analyzes infertility treatment cycles performed in 2022 based on this national registry.</p><p><strong>Methods: </strong>Data were retrospectively collected from 201 certified infertility treatment institutions in Korea. Standardized treatment forms for intrauterine insemination (IUI) and in vitro fertilization (IVF) were submitted to the Health Insurance Review and Assessment Service for all infertility treatment cycles conducted in 2022.</p><p><strong>Results: </strong>A total of 200,007 infertility treatment cycles were reported in 2022, consisting of 33,137 IUI cycles and 166,870 IVF cycles. Among IVF cycles, 64.6% were initiated for fresh embryo transfers and 35.4% for frozen-thawed embryo transfers. In IVF cycles, the overall clinical pregnancy rate per embryo transfer was 30.2% for fresh and 42.0% for frozen-thawed embryo transfers. The proportion of single embryo transfers has risen steadily since 2019. The most common indication for IVF was diminished ovarian reserve, while IUI was mainly performed for unexplained or male factor infertility.</p><p><strong>Conclusion: </strong>Nationwide infertility treatment cycle reporting in Korea has enabled detailed monitoring of infertility treatment trends and outcomes. The data show a substantial increase in IVF utilization, a growing preference for frozen-thawed embryo transfer, and broader adoption of single embryo transfer consistent with global practices. Further integration with birth outcome data and longitudinal patient tracking will be essential to evaluate cumulative success rates and overall effectiveness. This national registry provides a foundation for optimizing infertility care and facilitates international benchmarking.</p>","PeriodicalId":46409,"journal":{"name":"Clinical and Experimental Reproductive Medicine-CERM","volume":"52 4","pages":"299-309"},"PeriodicalIF":1.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12682406/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145702298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term use of dutasteride to treat androgenic alopecia in young men may lead to persistent abnormalities in semen parameters.","authors":"Young Jae Kim, Seoung Ryeol Lee, Young Dong Yu","doi":"10.5653/cerm.2024.07675","DOIUrl":"10.5653/cerm.2024.07675","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the long-term effects of dutasteride on male fertility and determine the cutoff treatment duration that causes significant and persistent decreases in semen parameters.</p><p><strong>Methods: </strong>This was a single-center, randomized, controlled study that evaluated 200 men (ages 28 to 39 years). Forty men were allocated to each study group, divided according to the duration of dutasteride treatment, as follows: <6 months (group 1), 6-12 months (group 2), 13-18 months (group 3), 19-24 months (group 4), and >24 months (group 5). All subjects received dutasteride 0.5 mg/day for management of androgenetic alopecia then discontinued dutasteride for 6 months.</p><p><strong>Results: </strong>The baseline mean testosterone level in the study subjects was 4.8 ng/mL. No significant differences were found between study groups in sperm concentration, normal morphology, and vitality. Semen volume and sperm total/progressive motility were significantly reduced as the duration of dutasteride treatment increased. All study groups showed an increase in total sperm motility and semen volume after discontinuation of dutasteride. Compared with group 1, groups 2-5 showed significant decreases in semen volume and sperm total motility, with the odds ratios becoming smaller as the duration of dutasteride treatment increased. Receiver operating characteristic analysis showed the cutoff values for persistent impairment of semen volume and total sperm motility to be 17.8 and 20.3 months, respectively.</p><p><strong>Conclusion: </strong>Long-term use of dutasteride may lead to male infertility by persistently impairing semen volume and sperm motility.</p>","PeriodicalId":46409,"journal":{"name":"Clinical and Experimental Reproductive Medicine-CERM","volume":" ","pages":"376-385"},"PeriodicalIF":1.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12682408/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"WT1 pathogenic variant in azoospermic infertile men with an isolated undescended testis.","authors":"Neda Sharifi, Parnaz Borjian Boroujeni, Kaveh Haratian, Marjan Sabbaghian, Anahita Mohseni Meybodi","doi":"10.5653/cerm.2024.07584","DOIUrl":"10.5653/cerm.2024.07584","url":null,"abstract":"<p><strong>Objective: </strong>An undescended testis (UDT) is a testicle that has not moved into the scrotum before birth. UDTs are linked to reduced fertility, primarily due to compromised semen quality and potential dysfunction in Sertoli and Leydig cells. Additionally, the Wilms tumor 1 (WT1) gene is crucial for spermatogenesis, as it regulates the polarity of Sertoli cells and the steroidogenesis in Leydig cells. Our study aimed to identify novel UDT-causing WT1 variants within a cohort of 60 unrelated men with infertile hypergonadotropic hypogonadism.</p><p><strong>Methods: </strong>In this case-control study, the coding regions and the intronic boundaries of the second and ninth exon of WT1 were sequenced using Sanger sequencing. DNA from 60 fertile men served as the control group. In silico analysis of the variants was also conducted.</p><p><strong>Results: </strong>The study identified multiple intronic and exonic variations in both the patient and control groups. Notably, a haplotype consisting of two heterozygous C>T variations in the intronic region of the splice donor site of exon 9 was observed in 11 patients but was absent in the control group. Of these variations, only one has been previously reported in Single Nucleotide Polymorphism Database (dbSNP) as rs587776576 (NC_000011.10: g.32391967C>T; NM_000378.4:c.1372+14G>A).</p><p><strong>Conclusion: </strong>The rs587776576 mutation is pathogenic. It exhibited a significant association (p=0.022), indicating its association with infertility and UDT in the Iranian population. This research could broaden the spectrum of WT1 variations and underscore the importance of these variants in the genetic etiology of UDT and infertility. These findings provide a foundation for clinical diagnosis and genetic counseling.</p>","PeriodicalId":46409,"journal":{"name":"Clinical and Experimental Reproductive Medicine-CERM","volume":" ","pages":"394-400"},"PeriodicalIF":1.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12682410/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144112157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Photobiomodulation is more effective than long-term scrotal hyperthermia in improving testis tissue and spermatogenesis in mice with busulfan-induced azoospermia.","authors":"Fakhredin Aqajanpor, Bahman Jalali Kondori, Mohammad Hossein Asadi, Mehdi Raei, Maryam Ghasem Nezhadian, Hossein Bahadoran","doi":"10.5653/cerm.2024.07430","DOIUrl":"10.5653/cerm.2024.07430","url":null,"abstract":"<p><strong>Objective: </strong>The use of photobiomodulation (PBM) for tissue repair has gained acceptance. This study investigated and compared the effects of PBM on mice exposed to scrotal hyperthermia and busulfan.</p><p><strong>Methods: </strong>Forty 8-week-old adult mice were divided into five groups: (I) control, (II) hyperthermia, (III) busulfan, (IV) hyperthermia+PBM, and (V) busulfan+PBM. To induce azoospermia in groups II and IV, the scrotum of the mice was exposed to water at 43 °C every other day for 5 weeks. In groups III and V, a single dose of busulfan (45 mg/kg) was administered intraperitoneally. Mice in groups IV and V received laser irradiation (0.03 J/cm2/sec) every other day for 35 days.</p><p><strong>Results: </strong>Molecular data analysis revealed that the levels of glutathione and the expression of proliferating cell nuclear antigen (Pcna) and stimulated by retinoic acid gene 8 (Stra8) genes were significantly higher in the busulfan+PBM group than in the hyperthermia+PBM group. Additionally, the number of testicular cells, tissue volume, and sperm parameters were also markedly higher in the busulfan+PBM group. Furthermore, this group exhibited a notable increase in serum testosterone levels.</p><p><strong>Conclusion: </strong>The results demonstrated that laser therapy enhances testicular function and spermatogenesis by reducing the formation of reactive oxygen species and increasing the expression of mitotic genes following the induction of scrotal hyperthermia and busulfan injection. However, the effectiveness of PBM was greater in the busulfan+PBM group.</p>","PeriodicalId":46409,"journal":{"name":"Clinical and Experimental Reproductive Medicine-CERM","volume":" ","pages":"283-294"},"PeriodicalIF":1.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12411876/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144040519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clomiphene citrate improves sperm parameters in infertile men with idiopathic oligoasthenozoospermia.","authors":"Joyutpala Shukla, Shamsun Nahar Moni, Muhammad Mubasshir Hasan, Muhammad Ariful Islam, Amitun Nessa Shikha, Nur-Wa-Bushra Jahan, Shakeela Ishrat","doi":"10.5653/cerm.2024.07353","DOIUrl":"10.5653/cerm.2024.07353","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to observe the effect of clomiphene citrate on sperm parameters in infertile men diagnosed with idiopathic oligoasthenozoospermia.</p><p><strong>Methods: </strong>This randomized controlled trial involved 50 infertile men diagnosed with idiopathic oligoasthenozoospermia, all of whom had normal serum testosterone and follicle-stimulating hormone levels. The participants were divided into two groups. The first group (n=25) received a daily dose of 50 mg of clomiphene citrate in tablet form for 3 months, while the second group (n=25) was given a placebo. Sperm concentration, sperm motility, and serum testosterone levels were measured at the start of the study and after 3 months of treatment. Changes in these parameters were then assessed and compared between the two groups.</p><p><strong>Results: </strong>There was a significant increase in the mean sperm count (9.17±4.11 million/mL vs. 13.88±7.27 million/mL), progressive motility (14.67±7.03 vs. 21.42±11.9), total motile sperm count (3.53±3.08 million vs. 7.81±7.10 million), and mean serum testosterone levels (371.97±88.51 ng/dL vs. 805.94±290.77 ng/dL) in the clomiphene citrate group. In contrast, the changes in the placebo group were not significant. Post-treatment severe oligozoospermia was substantially lower in the clomiphene citrate group (odds ratio, 0.31) compared to the placebo group. Additionally, half of the participants in the clomiphene citrate group experienced a statistically significant upgrade in World Health Organization (WHO) sperm concentration categories, versus 27.3% in the placebo group.</p><p><strong>Conclusion: </strong>Clomiphene citrate improves sperm count and motility, leading to upgrades in WHO sperm concentration categories in infertile men with idiopathic oligoasthenozoospermia.</p>","PeriodicalId":46409,"journal":{"name":"Clinical and Experimental Reproductive Medicine-CERM","volume":"52 3","pages":"252-258"},"PeriodicalIF":1.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12411873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144973770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of oxidation-reduction potential in follicular fluid on intracytoplasmic sperm injection outcomes.","authors":"Minh Tam Le, Thai Thanh Thi Nguyen, Trung Van Nguyen, Quoc Huy Vu Nguyen","doi":"10.5653/cerm.2024.07136","DOIUrl":"10.5653/cerm.2024.07136","url":null,"abstract":"<p><strong>Objective: </strong>Follicular fluid (FF) oxidation-reduction potential (ORP) has shown promise as a predictor for in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) outcomes has been demonstrated. This study aimed to determine the association between the ORP in FF and IVF/ICSI outcomes.</p><p><strong>Methods: </strong>This cross-sectional study involved data collection from 341 couples undergoing IVF/ICSI treatment. The FF sample was taken from the first follicle to exceed 18 mm during oocyte retrieval and was analyzed for ORP using the MiOXSYS system (Caerus Biotechnologies).</p><p><strong>Results: </strong>ORP in FF exhibited a statistically significant negative correlation with the fertilization rate (correlation coefficient, -0.126; p=0.019). The ORP levels in the FF from the group with a lower fertilization rate (<80%) were significantly higher than those in the group with a higher fertilization rate (≥80%) (89.90 mV vs. 78.98 mV, p=0.030). No significant correlations were found between ORP in FF and other outcomes.</p><p><strong>Conclusion: </strong>Our findings suggested that the ORP in FF may be correlated with the fertilization rate and could be evaluated as a predictor of fertilization in ICSI.</p>","PeriodicalId":46409,"journal":{"name":"Clinical and Experimental Reproductive Medicine-CERM","volume":" ","pages":"236-243"},"PeriodicalIF":1.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12411878/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142808036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical pregnancy rates after two different methods of laser-assisted hatching applied to vitrified-warmed day-3 embryos or day-5 blastocysts.","authors":"Woo Jeong Kim, Byung Chul Jee","doi":"10.5653/cerm.2024.07073","DOIUrl":"10.5653/cerm.2024.07073","url":null,"abstract":"<p><strong>Objective: </strong>Laser-assisted hatching (LAH) employs two distinct techniques: thinning and breaching. This study aimed to compare the clinical efficacy of combined thinning and breaching versus breaching alone in vitrified-warmed embryo or blastocyst transfer cycles.</p><p><strong>Methods: </strong>In total, 110 vitrified-warmed day-3 embryo transfer cycles and 50 vitrified-warmed day-5 blastocyst transfer cycles were retrospectively selected. All transfers were performed between 2021 and 2022 at a university-based infertility center. Combined thinning and breaching involved thinning either one-quarter or one-sixth of the zona pellucida circumference combined with breaching at a single point.</p><p><strong>Results: </strong>In vitrified-warmed day-3 embryo transfer cycles, the 'thinning and breaching' and 'breaching only' groups were similar regarding the median age of the woman (36 years vs. 37 years, respectively), number of embryos transferred (2 vs. 2), and embryo score (89 vs. 31.5). The clinical pregnancy rate (PR) (23.5% vs. 21.1%), embryo implantation rate (IR) (11.4% vs. 11.3%), and clinical miscarriage rate (25% vs. 37.5%) were also comparable between the two LAH groups. In vitrified-warmed day-5 blastocyst transfer cycles, the combination and breaching-only groups were similar in the median age of the woman (36 years vs. 36.5 years, respectively), number of blastocysts transferred (1 vs. 1), and blastocyst score (45 vs. 31.5). The clinical PR (45.5% vs. 42.9%), IR (35.4% vs. 33.3%), and clinical miscarriage rate (20% vs. 33.3%) were also similar between groups.</p><p><strong>Conclusion: </strong>Breaching alone displayed similar efficacy to combined thinning and breaching in terms of clinical PR, IR, and miscarriage rate. Thus, breaching alone appears sufficient to achieve favorable pregnancy outcomes.</p>","PeriodicalId":46409,"journal":{"name":"Clinical and Experimental Reproductive Medicine-CERM","volume":" ","pages":"244-251"},"PeriodicalIF":1.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12411877/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of granulocyte-macrophage colony-stimulating factor in inducing autophagy in the spermatozoa of patients with asthenoteratozoospermia.","authors":"Tahereh Gheliji, Mohammad Hosain Haidari, Marefat Ghaffari Novin, Zahra Shams Mofarahe, Mahsa Kazemi, Latif Gachkar, Pourya Raee, Bahareh Karimi, Hamid Nazarian","doi":"10.5653/cerm.2024.07479","DOIUrl":"10.5653/cerm.2024.07479","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study is to investigate the effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) treatment on the autophagy process and sperm parameters in individuals with asthenoteratozoospermia.</p><p><strong>Methods: </strong>Twenty semen samples from patients diagnosed with asthenoteratozoospermia were divided into control and treatment groups. Subsequently, 2 ng/mL of GM-CSF was added to the treatment group samples. All samples were then incubated for 1 hour. Post-incubation, the protein levels of light chain 3 II (LC3-II)/LC3-I and autophagy related 7 (Atg7), which are well-known autophagy markers, along with sperm motility, viability, and sperm DNA fragmentation, were analyzed in both study groups.</p><p><strong>Results: </strong>Our study demonstrated significant increases in LC3-II/LC3-I and Atg7 levels, as well as in sperm motility, in the GM-CSF group compared to the control group (p<0.0001). Furthermore, GM-CSF treatment significantly reduced necrotic cell death in the GM-CSF group relative to the control group (p<0.01). There were no significant differences between the groups in terms of sperm viability and DNA fragmentation (p>0.05).</p><p><strong>Conclusion: </strong>These results revealed that GM-CSF has the potential to significantly induce autophagy in sperm and enhance sperm motility in patients with asthenoteratozoospermia, without adversely affecting sperm viability and DNA integrity. These findings suggest that modifying autophagy with physiological and safe components like GM-CSF may become a promising therapeutic strategy for treating male infertility in the near future.</p>","PeriodicalId":46409,"journal":{"name":"Clinical and Experimental Reproductive Medicine-CERM","volume":" ","pages":"275-282"},"PeriodicalIF":1.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12411871/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent trends in polycystic ovary syndrome treatment based on adult stem cell therapies.","authors":"Hyeri Park, Ji Woong Han, Gi Jin Kim","doi":"10.5653/cerm.2024.07248","DOIUrl":"10.5653/cerm.2024.07248","url":null,"abstract":"<p><p>Adult stem cell therapy has emerged as a prominent area of interest in regenerative medicine, drawing attention from numerous researchers who are investigating its potential for treating degenerative diseases, especially those affecting the reproductive system. Despite the growing focus, critical elements such as the optimization of treatment parameters (e.g., transplantation [Tx] route, cell dosage) and enhancement of therapeutic efficacy are still areas of uncertainty. This review paper presents a thorough analysis of recent preclinical and clinical studies on adult stem cell therapy for ovarian dysfunction, specifically targeting conditions like polycystic ovary syndrome (PCOS). By examining these studies, the review seeks to clarify the current state of knowledge and pinpoint gaps in understanding, thereby establishing a robust foundation for future advancements in adult stem cell therapies aimed at ovarian dysfunction. Ultimately, this paper aims to offer valuable insights that could lead to improved treatment strategies in the field of reproductive system diseases.</p>","PeriodicalId":46409,"journal":{"name":"Clinical and Experimental Reproductive Medicine-CERM","volume":" ","pages":"189-201"},"PeriodicalIF":1.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12411874/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}